Notícias e Atividades da Lexicon Pharmaceuticals

Lexicon Pharmaceuticals é uma das ...

• Russell 3000;
• TOB Iconic 10,000.

Lexicon Pharmaceuticals é uma empresa listada sob o símbolo LXRX (US).

Veja o organograma con seus 30 executivos principais

Biografias mais buscadas da Lexicon Pharmaceuticals

• Mike Exton, Chief Executive Officer and Director
• Raymond Debbane, Chairman of the Board
• Diane Sullivan, Director

Recentes movimentos de executivos em Lexicon Pharmaceuticals

• Scott Coiante, ingressou na Companhia como Chief Financial Officer  (Notícia publicada em 2 de janeiro de 2025).
• Robert Lefkowitz, Director, se aposentou  (Notícia publicada em 21 de novembro de 2024).
• Ivan Cheung, ingressou na Companhia como Director  (Notícia publicada em 21 de novembro de 2024).

Clique aqui para ver outras movimentos em Lexicon Pharmaceuticals

Criar um alerta
para seguir os movimentos de executivos da Lexicon Pharmaceuticals.

Lexicon Pharmaceuticals possui 2.339 concorrentes concorrentes Eurofins (Luxemburgo), Lonza (Suíça) e Biogen (Estados Unidos).

Popular M&A news in Biotecnologia

• Jade Biosciences and Aerovate Therapeutics have announced they will merge  (publicado em 30 de abril de 2025)..
• Deepull acaba de anunciar uma arrecadação de fundos de 50 milhões de dólares. (publicado em 29 de abril de 2025).
• Biolinq acaba de anunciar uma arrecadação de fundos de 100 milhões de dólares. (publicado em 23 de abril de 2025).

Outros contatos sugeridos na indústria do Biotecnologia

• Herriot Tabuteau - Chief Executive Officer and Director da Axsome Therapeutics
• Kristina Burow - Director da Scholar Rock
• Steven Gillis - Chairman of the Board da VBI Vaccines

Saiba mais sobre a indústria do Biotecnologia

Últimos comunicados de imprensa de Lexicon Pharmaceuticals

• Lexicon Reveals “into the Dark” Awareness Campaign About Vulnerable and Dangerous Period of Time Faced by Heart Failure Patients Following Hospitalization | Lexicon Pharmaceuticals, Inc.Lexicon Reveals “into the Dark” Awareness Campaign About Vulnerable a
• New Analyses of Sotagliflozin Showing Time to Clinical Benefit Presented at the American College of Cardiology’s 72nd Annual Scientific Session Together with World Heart Federation’s World Congress of Cardiology | Lexicon Pharmaceuticals, Inc.New Analyses
• Lexicon Pharmaceuticals Reports Fourth Quarter 2022 Financial Results and Provides Business Update | Lexicon Pharmaceuticals, Inc.Lexicon Pharmaceuticals Reports Fourth Quarter 2022 Financial Results and Provides Business Update
• Lexicon Pharmaceuticals to Host Fourth Quarter 2022 Financial Results Conference Call and Webcast on March 2, 2023 | Lexicon Pharmaceuticals, Inc.Lexicon Pharmaceuticals to Host Fourth Quarter 2022 Financial Results Conference Call and Webcast on March 2,
• New Analyses of Sotagliflozin to Be Presented at the American College of Cardiology’s 72nd Annual Scientific Session Together with World Heart Federation’s World Congress of Cardiology | Lexicon Pharmaceuticals, Inc.New Analyses of Sotagliflozin to Be Pre
• Lexicon Pharmaceuticals to Participate in the 41st Annual JP Morgan Healthcare Conference | Lexicon Pharmaceuticals, Inc.Lexicon Pharmaceuticals to Participate in the 41st Annual JP Morgan Healthcare Conference
• Lexicon Announces Topline Results from Phase 2 Proof-of-Concept Study of LX9211 in Postherpetic Neuralgia | Lexicon Pharmaceuticals, Inc.Lexicon Announces Topline Results from Phase 2 Proof-of-Concept Study of LX9211 in Postherpetic Neuralgia
• Lexicon Pharmaceuticals to Participate in the 34th Annual Piper Sandler Healthcare Conference and the 5th Annual Evercore ISI HealthCONx Conference | Lexicon Pharmaceuticals, Inc.Lexicon Pharmaceuticals to Participate in the 34th Annual Piper Sandler Heal
• Lexicon’s LX9211 Shows Significant and Consistent Benefits in the Treatment of Painful Diabetic Neuropathy in Full Results from the Phase 2 RELIEF-DPN-1 Trial Presented at the 16th Annual Pain Therapeutics Summit | Lexicon Pharmaceuticals, Inc.Lexicon’s L
• Lexicon Pharmaceuticals to Participate in the 13th Annual Jefferies London Healthcare Conference | Lexicon Pharmaceuticals, Inc.Lexicon Pharmaceuticals to Participate in the 13th Annual Jefferies London Healthcare Conference
• View more press releases Close

Redes sociais sobre Lexicon Pharmaceuticals

• Lexicon Pharmaceuticals na Wikipedia, Google News e Yahoo Finance
• Lexicon Pharmaceuticals na LinkedIn, Twitter e YouTube